Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study

医学 氟康唑 假丝酵母病 多中心研究 回顾性队列研究 真菌血症 白霉素类 血流感染 重症监护医学 内科学 真菌病 抗真菌 外科 卡斯波芬金 随机对照试验 皮肤病科
作者
Antonio Vena,Giusy Tiseo,Marco Falcone,Claudia Bartalucci,Cristina Marelli,Mario Cesaretti,Vincenzo Di Pilato,Pilar Escribano,Arianna Forniti,Daniele Roberto Giacobbe,Jesús Guinea,Alessandro Limongelli,Antonella Lupetti,Marina Machado,Małgorzata Mikulska,Jon Salmanton‐García,Ana Soriano-Martín,Lucia Taramasso,Maricela Valerio,Emilio Bouza
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
被引量:3
标识
DOI:10.1093/cid/ciae603
摘要

Abstract Background This study assesses the impact of fluconazole resistance on 30-day all-cause mortality and 1-year recurrence in patients with Candida parapsilosis bloodstream infections (BSI). Methods A multicenter retrospective study was performed at 3 hospitals in Italy and Spain between 2018 and 2022. Adult patients with positive blood cultures for C. parapsilosis who received appropriate targeted therapy with either echinocandins or fluconazole were included. Results Among 457 patients, 196 (42.9%) had fluconazole-resistant C. parapsilosis (FLZR-CP) BSI and 261 (57.1%) had fluconazole-susceptible C. parapsilosis (FLZS-CP) BSI. All FLZR-CP patients received targeted echinocandins, while FLZS-CP patients received either echinocandins (60.5%) or fluconazole (39.5%). Unadjusted 30-day all-cause mortality rates were 28.6% for FLZR-CP and 28.4% for FLZS-CP (log-rank test, P = .998). In multivariable analysis, increased mortality was associated with age (adjusted hazard ratio [aHR] 1.03 per year; 95% confidence interval [CI], 1.01–1.05; P = .0005), solid tumor (aHR 1.91; 95% CI, 1.06–3.46; P = .0302), previous antifungal treatment (aHR 1.84; 95% CI, 1.12–3.10; P = .0192), and septic shock (aHR 2.39; 95% CI, 1.42–4.06; P = .0010), but not fluconazole resistance (aHR 1.00; 95% CI, .62–1.63; P = .9864) nor the type of initial antifungal therapy (aHR 1.46; 95% CI, .69–3.06; P = .3202). Propensity score-matched analysis showed no 30-day all-cause mortality difference between echinocandin-treated FLZR-CP and fluconazole-treated FLZS-CP patients (HR 0.81; 95% CI, .37–1.75; P = .5915). However, a higher 1-year recurrence risk was observed in FLZR-CP patients (odds ratio, 7.37; 95% CI, 2.11–25.80; P = .0018). Conclusions Our results suggest that fluconazole resistance is not associated with a higher mortality risk in patients with C. parapsilosis BSI, though 1-year recurrence rates were higher in the FLZR-CP group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wl20130000完成签到,获得积分10
1秒前
1秒前
1秒前
日月完成签到,获得积分10
3秒前
踏实的书包完成签到,获得积分10
3秒前
科学飞龙完成签到,获得积分10
4秒前
nautilus完成签到,获得积分10
4秒前
无花果应助Zhangqiang采纳,获得10
4秒前
5秒前
夏沫完成签到,获得积分10
5秒前
田様应助aaaaaa采纳,获得10
6秒前
6秒前
bobo发布了新的文献求助10
6秒前
zhangwj226完成签到,获得积分10
6秒前
Huobol完成签到,获得积分10
7秒前
小彻发布了新的文献求助10
7秒前
顾矜应助超帅的念寒采纳,获得10
7秒前
两袖清风发布了新的文献求助10
7秒前
8秒前
lxl1996完成签到,获得积分10
8秒前
9秒前
9秒前
大方钥匙完成签到,获得积分10
9秒前
nico发布了新的文献求助10
9秒前
生动的沧海完成签到,获得积分10
10秒前
所所应助zhenglei9058采纳,获得10
10秒前
10秒前
大蜥蜴完成签到,获得积分10
10秒前
上官若男应助研友_LN32Mn采纳,获得10
10秒前
10秒前
xs6661驳回了打打应助
11秒前
青木蓝发布了新的文献求助10
11秒前
aaaa完成签到,获得积分10
11秒前
刁刁发布了新的文献求助10
12秒前
小彻完成签到,获得积分10
13秒前
大方钥匙发布了新的文献求助10
13秒前
13秒前
虚心夏真发布了新的文献求助10
14秒前
鲍binyu完成签到,获得积分10
14秒前
14秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
TOWARD A HISTORY OF THE PALEOZOIC ASTEROIDEA (ECHINODERMATA) 1000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
The Social Work Ethics Casebook(2nd,Frederic G. R) 600
Handbook of Social and Emotional Learning 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5118645
求助须知:如何正确求助?哪些是违规求助? 4324517
关于积分的说明 13472791
捐赠科研通 4157640
什么是DOI,文献DOI怎么找? 2278510
邀请新用户注册赠送积分活动 1280244
关于科研通互助平台的介绍 1219029